21703-52-6

Usage

Uses

2-Hydrazino-4-methylquinoline is used as a pharmaceutical intermediate.

Upstream product

• 634-47-9 2-chloro-4-methylquinoline 
• 607-66-9 4-methylquinolin-2-ol 

Downstream Products

• 35359-25-2 5-methyl-s-triazolo<4,3-a>quinoline 
• 71508-71-9 1-(4'-methyl-2'-quinolyl)-3-(2'pyridyl)-1,2-diaza-2-propene 
• 71508-44-6 1-(4-chlorobenzylidene)-2-(4-methylquinolin-2-yl)hydrazine 
• 209730-33-6 N-(4-Methyl-quinolin-2-yl)-N'-[1-(3-nitro-phenyl)-meth-(E)-ylidene]-hydrazine 
• 90146-65-9 benzaldehyde-(4-methyl-[2]quinolylhydrazone) 
• 209730-28-9 1-(4-methoxybenzylidene)-2-(4-methylquinolin-2-yl)hydrazine 
• 209730-34-7 N-(4-Methyl-quinolin-2-yl)-N'-[1-(2-nitro-phenyl)-meth-(E)-ylidene]-hydrazine 
• 90146-65-9 1-benzylidene-2-(4-methylquinolin-2-yl)hydrazine 

Relevant academic research and scientific papers

Oxiranes with quinolone substitution: Stereoselective synthesis and antiviral activity

A series of new quinoline substituted oxiranes were synthesized by the reaction of 2-N-(chloroacetyl)-1-(4'-methyl-2'-quinolinyl) hydrazine and aromatic aldehydes. These compounds were tested against encephalomyocarditis virus (EMVC) and only two compounds exhibited protection against the virus.

CONDENSED RING PYRIDINE COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-2 (S1P2) RECEPTORS

The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and R3 are defined in the specification. Said compounds are useful for treating a disease or condition of a mammal selected from the group consisting of ocular diseases; systemic vascular barrier related diseases; allergies and other inflammatory diseases; cardiac diseases or conditions; fibrosis; pain and wounds.

NOVEL FUSED TRIAZOLONES AND THE USES THEREOF

This invention relates to novel compounds having the structural diagram (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.